Trial Profile
Antitumor Immune Responses in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: a Phase II Study With Trastuzumab and Concomitant Weekly Paclitaxel in Patients With HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Docetaxel; Epirubicin; Paclitaxel
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Dec 2014 New trial record